story of the week
Atezolizumab With Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
J. Clin. Oncol 2022 Jun 28;[EPub Ahead of Print], J Huober, CH Barrios, N Niikura, M Jarząb, YC Chang, SL Huggins-Puhalla, J Pedrini, L Zhukova, V Graupner, D Eiger, V Henschel, N Gochitashvili, C Lambertini, E Restuccia, H ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.